HomeAI · summaries
Storia in 4 fonti
Spyre tumbles as immune drug misses mark in rheumatoid arthritis
The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Spyre tumbles as immune drug misses mark in rheumatoid arthritis
The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.
- ·
endpoints.news
Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data
Spyre deprioritizes anti-TL1A drug SPY072 in RA after Phase 2 misses its bar; shares dip 12% as SKYLINE UC data nears in September.
